Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Clamping down on a cancer-causing protein

28.01.2002


Many of today’s medicines were discovered by trial and error: a substance is found which helps alleviate the symptoms of a disease, and it may take years before scientists really understand how it works. Typically they find that a drug has its effects by attaching itself to a particular molecule in a cell and blocking part of its activity, the way you might prevent someone from turning a light on or off by putting a lock over the switch. Scientists now hope to take the opposite approach, and custom-design drugs to block specific switches. To do so, they will need precise “technical diagrams” of the molecules they want to lock up. Now the Italian researcher Giulio Superti-Furga and his colleagues at the European Molecular Biology Laboratory (EMBL) have produced such a diagram of a cancer-causing molecule, and their work gives researchers a good idea of how to go about designing drugs. Their report appears in the current issue of the journal Cell.



The molecule, a protein called Abl, is produced in all human cells. Some people acquire a defect in the genetic blueprint for this molecule, causing their bodies to create a malformed version called BCR-Abl. For years researchers have known that this defective molecule is linked to forms of the deadly disease leukemia.

Abl has important jobs to perform within cells. One of its chief roles is to get information from proteins and pass it on to other molecules – like a radio operator who receives a message telling him to turn on an alarm. If Abl is defective, it might not hear incoming messages, or it might continually send off alarms, even when it hasn’t been told to do so.


One of the messages that Abl transmits tells the cell, “It’s time to divide.” Normally this signal shouldn’t be sent too often, but BCR-Abl and other defective forms of the protein are stuck in transmission mode, leading to a very high rate of cell division and thus cancer.

“Abl needs to be switched off, and one of the chief questions that people have had is whether other molecules are needed to throw the switch, or whether Abl can turn itself off,” says Giulio Superti-Furga. “We’ve now discovered that there is an internal switch that allows it to shut itself down. BCR-Abl is missing an important structural piece of the protein, a sort of clamp that holds things in the right places, and the molecule can’t stop sending signals.”

The key thing that Superti-Furga and colleagues Helma Pluk and Karel Dorey have discovered is that the clamp lies in a part of the molecule quite distant from the machinery that actually transmits signals. Clinical trials are currently being performed with a drug called STI571, which appears to directly block the transmission machinery, but some patients are able to develop resistance to the drug. This might be because the real switch is still turned on.

The EMBL researchers discovered the clamp by creating artificial versions of Abl missing certain parts, and then examining the molecule’s transmitting capabilities in the test tube. When they removed a cap section that connects itself to two major substructures of the molecule, they discovered that Abl could no longer be shut down.

“BCR-Abl doesn’t have this cap, so other parts of the the molecule probably move out of their proper positions,” Superti-Furga says. “If you imitate this by removing the cap from the normal form of Abl, or preventing the cap from clamping onto the proper parts of the molecule, the switch gets frozen.”

This explains why several roads might lead to the same result – cancer. Even if the cap structure is present, other molecules might interfere with it and break the internal switch. By showing that the cap is essential in Abl’s switch, the researchers have provided a very good place to start in designing new drugs for this specific type of cancer.



Russell Hodge | alphagalileo
Further information:
http://www.embl-heidelberg.de

More articles from Health and Medicine:

nachricht PET imaging tracks Zika virus infection, disease progression in mouse model
20.09.2017 | US Army Medical Research Institute of Infectious Diseases

nachricht 'Exciting' discovery on path to develop new type of vaccine to treat global viruses
18.09.2017 | University of Southampton

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Tiny lasers from a gallery of whispers

New technique promises tunable laser devices

Whispering gallery mode (WGM) resonators are used to make tiny micro-lasers, sensors, switches, routers and other devices. These tiny structures rely on a...

Im Focus: Ultrafast snapshots of relaxing electrons in solids

Using ultrafast flashes of laser and x-ray radiation, scientists at the Max Planck Institute of Quantum Optics (Garching, Germany) took snapshots of the briefest electron motion inside a solid material to date. The electron motion lasted only 750 billionths of the billionth of a second before it fainted, setting a new record of human capability to capture ultrafast processes inside solids!

When x-rays shine onto solid materials or large molecules, an electron is pushed away from its original place near the nucleus of the atom, leaving a hole...

Im Focus: Quantum Sensors Decipher Magnetic Ordering in a New Semiconducting Material

For the first time, physicists have successfully imaged spiral magnetic ordering in a multiferroic material. These materials are considered highly promising candidates for future data storage media. The researchers were able to prove their findings using unique quantum sensors that were developed at Basel University and that can analyze electromagnetic fields on the nanometer scale. The results – obtained by scientists from the University of Basel’s Department of Physics, the Swiss Nanoscience Institute, the University of Montpellier and several laboratories from University Paris-Saclay – were recently published in the journal Nature.

Multiferroics are materials that simultaneously react to electric and magnetic fields. These two properties are rarely found together, and their combined...

Im Focus: Fast, convenient & standardized: New lab innovation for automated tissue engineering & drug

MBM ScienceBridge GmbH successfully negotiated a license agreement between University Medical Center Göttingen (UMG) and the biotech company Tissue Systems Holding GmbH about commercial use of a multi-well tissue plate for automated and reliable tissue engineering & drug testing.

MBM ScienceBridge GmbH successfully negotiated a license agreement between University Medical Center Göttingen (UMG) and the biotech company Tissue Systems...

Im Focus: Silencing bacteria

HZI researchers pave the way for new agents that render hospital pathogens mute

Pathogenic bacteria are becoming resistant to common antibiotics to an ever increasing degree. One of the most difficult germs is Pseudomonas aeruginosa, a...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

“Lasers in Composites Symposium” in Aachen – from Science to Application

19.09.2017 | Event News

I-ESA 2018 – Call for Papers

12.09.2017 | Event News

EMBO at Basel Life, a new conference on current and emerging life science research

06.09.2017 | Event News

 
Latest News

Molecular Force Sensors

20.09.2017 | Life Sciences

Producing electricity during flight

20.09.2017 | Power and Electrical Engineering

Tiny lasers from a gallery of whispers

20.09.2017 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>